Identification of a survivin-derived peptide that induces HLA-A* 0201-restricted antileukemia cytotoxic T lymphocytes
S Siegel, J Steinmann, N Schmitz, R Stuhlmann… - Leukemia, 2004 - nature.com
S Siegel, J Steinmann, N Schmitz, R Stuhlmann, P Dreger, M Zeis
Leukemia, 2004•nature.comProphylaxis of deep vein thrombosis with fixed low-dose warfarin in patients with multiple
myeloma receiving first-line combined thalidomide-dexamethasone. Hematol J 2003; 4:
S251, abstract). However, others could not demonstrate a beneficial effect when using 1mg
fixed-dose warfarin, but also reported comparable VTE incidences with their control arm
when changing to LMWH prophylaxis.(Zangari M, Barlogie B, Saghafifar F et al. Effect of
anticoagulation on development and recurrence of deep vein thrombosis (DVT) in multiple …
myeloma receiving first-line combined thalidomide-dexamethasone. Hematol J 2003; 4:
S251, abstract). However, others could not demonstrate a beneficial effect when using 1mg
fixed-dose warfarin, but also reported comparable VTE incidences with their control arm
when changing to LMWH prophylaxis.(Zangari M, Barlogie B, Saghafifar F et al. Effect of
anticoagulation on development and recurrence of deep vein thrombosis (DVT) in multiple …
Prophylaxis of deep vein thrombosis with fixed low-dose warfarin in patients with multiple myeloma receiving first-line combined thalidomide-dexamethasone. Hematol J 2003; 4: S251, abstract). However, others could not demonstrate a beneficial effect when using 1mg fixed-dose warfarin, but also reported comparable VTE incidences with their control arm when changing to LMWH prophylaxis.(Zangari M, Barlogie B, Saghafifar F et al. Effect of anticoagulation on development and recurrence of deep vein thrombosis (DVT) in multiple myeloma patients treated with chemotherapy and thalidomide (Total therapy II). Hematol J 2003; 4: S248, abstract).
nature.com